ArticleFrontiers in pharmacology2019
Molecular Epidemiology of and Risk Factors for Extensively Drug-Resistant
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Epidemiological characteristics and non-linear risk factors of surgical site infections in patients with cancer: a propensity score-matched case-control study.Infection prevention in practice · 2026Article
- Study on pathogenic bacteria distribution and antimicrobial resistance in adult urinary tract infections in a tertiary hospital in Southern Jiangxi, China, 2021-2024.Frontiers in cellular and infection microbiology · 2026Article
- Epidemiology of Carbapenem-Resistant Klebsiella Pneumoniae Co-Producing MBL and OXA-48-Like in a Romanian Tertiary Hospital: A Call to Action.Antibiotics (Basel, Switzerland) · 2025Article
- Outbreak report of polymyxin-carbapenem-resistant Klebsiella pneumoniae causing untreatable infections evidenced by synergy tests and bacterial genomes.Scientific reports · 2023Article
- Prevalence and molecular characteristics of polymyxin-resistantFrontiers in cellular and infection microbiology · 2023Article
- Bacteriological Profile and Antimicrobial Susceptibility Patterns of Gram-Negative Bloodstream Infection and Risk Factors Associated with Mortality and Drug Resistance: A Retrospective Study from Shanxi, China.Infection and drug resistance · 2022Article
- Therapeutic Drug Monitoring of Ceftazidime-Avibactam Concentrations in Carbapenem-ResistantFrontiers in pharmacology · 2022Article
- Heteroresistance to Amikacin in Carbapenem-ResistantFrontiers in microbiology · 2021Article
- Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-ResistantFrontiers in pharmacology · 2021Article
- Clinical Observation and Prognostic Analysis of Patients WithFrontiers in cellular and infection microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.